Canadian Cancer Trials Group Bulletins


Recent Publication

The primary results of Canadian Cancer Trials Group IND.199 - A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients with Recurrent, Unresectable, Locally Advanced or Metastatic Carcimona of the Cervix - was recently published online in Gynecologic Oncology.

The study authors conclude that single agent temsirolimus has modest activity in cervical carcinoma with about two-thirds of patients exhibiting stable disease. Molecular markers for treatment benefit remain to be identified.

Tinker AV, Ellard S, Welch S, Moens F, Allo G, Tsao MS, Squire J, Tu D, Eisenhauer EA, Mackay H. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the Canadian Cancer Trials Group (Canadian Cancer Trials Group IND 199) (ONLINE). Gynecol Oncol 2013.